ATLAS ACS 2-TIMI 51 was a phase III, multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating an oral, direct factor Xa inhibitor (rivaroxaban) in subjects following an acute coronary syndrome. Subjects received low-dose aspirin therapy (75 to 100 mg/day), and enrollment was stratified based upon the intent of the investigator to administer a thienopyridine [Stratum 1 … Continue reading ATLAS ACS2-TIMI 51